Continued challenges with poor leadership at the C level. Company has not been profitable - negative EBITDA - in the last four years. Continued issues with FDA warning letters, legal issues with DOJ investigation, lawsuits. Irhythm is essentially a single product, single service, single market company that doesn’t make money. An attempt at an international launch has stalled and has been largely abandoned. None of that points to a sustainable future. I would not be surprised if the company were acquired and sold for parts in the next 12 months.